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The COVID-19 pandemic has created unprecedented hurdles to the delivery of care
to patients with cancer. Patients with hematologic malignancies appear to have a
greater risk of SARS-CoV-2 infection and severe disease due to myelosuppression and
lymphopenia. The first challenge, therefore, is how to continue to deliver effective, curative
therapy to vulnerable patients and at the same time avoid exposing them, and their health
care teams (HCT), to SARS-CoV-2. An additional challenge is the timely completion of
the diagnostic and staging studies required to formulate appropriate treatment plans.
Deferred procedures and avoidance of multiple trips to the surgical, diagnostic, and
laboratory suites require same day consolidation of all procedures. With laboratory
medicine absorbed by the need to deploy large scale COVID-testing, the availability of
routine molecular tests is affected. Finally, we are increasingly faced with the challenge of
making complex treatment decisions in SARS-CoV-2 positive patients with aggressive
but potentially curable blood cancers. When to treat, how to treat, when to wait, how
long to wait, how to predict and manage toxicities, and how to avoid compromising cure
rates remains unknown. We present an outline of the scientific, medical, and operational
challenges posed by the COVID-19 pandemic at selected American and European
institutions and offer our current view of the key elements of a response. While the peak
of the pandemic may be past us, in the absence of a vaccine risks remain, and our
alertness and response to future challenges need to be refined and consolidated.
Keywords: SARS-CoV-2, hematologic malignancies, COVID-19, lymphoma, myeloma, leukemia, CAR T-cell,
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INTRODUCTION
In December 2019, an outbreak of atypical pneumonia, with
severe acute respiratory syndrome (SARS), was identified in
Wuhan, China (1, 2). The rapid human-to-human transmission
of the new zoonotic coronavirus (SARS-CoV-2), that is
responsible for what is now known as coronavirus disease 2019
(COVID-19) led to a global outbreak, which on March 11, 2020
was declared a pandemic by the World Health Organization
(WHO). The COVID-19 pandemic is an unparalleled challenge
for the medical community and has created a multitude of
medical, logistical, financial, and public health challenges in the
delivery of optimal care for cancer patients, and in particular for
patients with hematologic malignancies.
Patients with leukemia, lymphoma, and myeloma frequently
visit the hospital or the outpatient clinic for treatment,
transfusion support, antibiotic therapy, management
of complications, and disease surveillance. In addition,
these patients often require prolonged hospitalizations,
myelosuppressive chemotherapy, and the use of high-
risk procedures such as autologous or allogeneic Stem Cell
Transplantation (SCT). Therefore, these patients are generally
immunocompromised due to the underlying malignancy
and/or anticancer therapy and are at higher risk of developing
infections (3).
Initial reports from China suggested that patients with cancer
had an estimated two-fold increased risk of contracting SARS-
CoV-2 than the general population and, if infected, also had a
higher risk of severe events (ICU admission, invasive ventilation,
or death) compared to patients without cancer (4). These risks
are likely to be greater in patients with hematologic malignancies,
leading to an urgent need to address the impact of the COVID-
19 pandemic on the care of these patients. Challenges include
equitable resource allocation, delivery of clinical care without
undue risk of exposure to patients and health care workers,
and the consent process during a time of restricted travel
and isolation.
Standard management of cancer patients has been impacted
first by efforts to limit exposures and new cases during the
acceleration phase (treatment while under a regime of isolation),
then by limited access to healthcare resources during the
“surge” period (deferment management), and finally by an after-
surge of new diagnoses, recurrences, and disease complications
that require initiation of treatment (post-surge planning for
deferred patients).
By searching PubMed for COVID-19 and leukemia, myeloma,
or lymphoma we found approximately 40 papers that matched.
Data are limited, but the outcomes of patients with cancer
who are COVID-19-positive at this time appear to be worse
than for COVID-negative patients (4), including patients with
hematologic malignancies.
The largest experience on COVID-19 in patients with
hematologic malignancies so far was reported by He et al.
(5). One-hundred and twenty-eight patients with hematologic
malignancies, hospitalized at two centers in Wuhan, China were
evaluated in a cohort study; 13 (10%) developed COVID-19.
Moreover, 226 health care providers were studied, 16 of which
developed COVID-19, and 11 were hospitalized. No significant
differences in baseline characteristics were observed between the
patients with hematologic malignancies who developed COVID-
19 and those who did not. However, COVID-19 appeared to be
more severe, and more deaths were reported, in the patients with
hematologic malignancies compared to the cohort of healthcare
providers who developed COVID-19.
Several papers have appeared, by individuals, groups of
specialists or under the auspices of scientific societies, to offer
an initial description of the clinical presentation of COVID-
19 in patients with hematologic malignancies and to advocate
for general recommendations of good clinical practice in this
pandemic period, for both adult and pediatric patients (6–21).
One interesting case report involved a SARS-CoV-2 infection in
a 39-year-old patient with chronic lymphocytic leukemia (CLL)
where the clinical and biochemical manifestations of COVID-
19 were partly masked by the coexisting CLL (6). One letter
by the University Hospital of Dublin reported on the positive
outcome of a young woman with refractory Hodgkin lymphoma
(HL) on pembrolizumab who wasinfected with SARS-CoV-2,
required intensive care service without intubation, and was safely
discharged from the hospital after 16 days (7). A French group
(8) reviewed the data of 25 consecutive adult patients admitted
to a Hematology Department in Paris with confirmed COVID-
19 infection and at least 10 days of follow-up. Twenty patients
had a lymphoid malignancy including 10 patients with multiple
myeloma (MM); there was relative overrepresentation of MM
patients in that cohort compared to the usual activity, suggesting
that MM patients might have a higher risk of developing SARS-
CoV-2 infection. Of the 18 patients with a follow-up, 52%
developed acute respiratory distress syndrome (ARDS), and 6
required mechanical ventilation; 9 of the patients with ARDS
died. Of note, many patients were older (>65 years), with one
or more comorbidity, which could have increased the severity of
COVID manifestations.
Specific guidelines have been proposed for chimeric antigen
receptor T-cell (CART) therapy (9), acute myeloid leukemia
and myelodysplastic syndromes (10–14), infections (15), chronic
myeloid leukemia (16), chronic lymphocytic leukemia (17), and
use of BTK inhibitors (18), which may have the potential benefit
of blunting the hyperinflammatory response to SARS-CoV-2, but
also potentially increasing the risk of secondary infections or
impaired humoral immunity (18).
For multiple myeloma patients, different papers proposed
recommendations specifically adapted to their management
during the COVID-19 pandemic, stemming from expert panels
or individual expert opinions (22–24).
Notwithstanding this plethora of papers, a practical,
comprehensive guide for clinicians involved in the path to cure
of patients with hematological malignancies is still lacking and
thus is urgently needed, especially if the number of COVID-19
positive cases increases worldwide and the lockdown of many
countries continues.
In this article, we attempt to provide some practical
suggestions on the management of patients with hematologic
malignancies during the COVID-19 pandemic. The manuscript
briefly covers practical issues such as delays in diagnosis,
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deferral of chemotherapy, utilization of SCT, modifications of
maintenance treatments, access to and utilization of supportive
measures, role and safety of targeted therapies, as well as ways
to mitigate these changes. Moreover, we will try to answer some
burning questions, such as: (1) Who and when should be tested?
(2) Is multiple testing needed? (3) Which therapies should be
considered? (4) What about older patients? (5) Should SCT
(autologous and allogeneic) be delayed?
DIAGNOSIS AND TESTING
The diagnostic facilities of clinical medicine and pathology
laboratories have also been directly or indirectly affected by
the pandemic. The urgent need for developing reliable tests for
SARS-CoV-2 infection and performing these analyses quickly
and reliably on a large scale have required the reorganization of
the activity of technicians and scientists to increase and optimize
the resources dedicated to viral testing. At the same time,
pathology departments have generally been facing a decrease in
their total caseloads in surgical pathology and cytology, because
elective surgeries were canceled in most hospitals and clinics,
and ambulatory consultations were reduced to aminimum.More
specifically however, in line with the selection of patients eligible
for surgery, there was an enrichment in complex surgical cases
or critical diagnoses. In addition, several pathology departments
in academic centers and large institutions have implemented
an autopsy program for COVID-19 patients, imposing the
application of strict biosafety precautions as recommended by the
CDC and other national societies, and requiring the allocation of
internal resources to that activity.
The laboratory diagnosis of hematologic malignancies
typically relies on multiple parameters starting with morphology
provided by the cytological examination of smears or
histopathologic assessment of tissues, with the addition of
immunophenotypical, molecular and genetic studies based
on the type of disease and its complexity. It requires the
intervention of certified pathologists or cytopathologists, clinical
scientists, and technicians. In different areas of the world where
the epidemics has been variably developing, variable rates of
infection among the medical and paramedical staff have been
reported, with direct consequences on themedical and diagnostic
operations. Moreover, in several institutions a rotating service
among the personnel has been implemented to allow social
distancing of the staff in the working places, and to preserve part
of the staff in case of an infection outburst.
Besides intra-laboratory factors, the main factor impacting
the diagnosis of hematologic malignancies is the acquisition
of diagnostic samples. In case of clinics or medical practices
using the services of outside laboratories, shipment of the
samples may be delayed. Probably the main challenge, for
several reasons detailed in the other sections, is that delay in
spontaneous presentation or referral of symptomatic patients,
and these may further face limited medical availability implying
additional delays. While the feasibility of blood drawing and
blood testing is in principle least compromised, bone marrow
aspiration, and biopsy which require qualified operators and
assistants, is possibly avoided in situations where it is considered
not absolutely necessary at first sight, potentially eliminating
the availability of important information. One major problem is
the performance of diagnostic biopsies of lymph nodes or other
masses suspicious for lymphoma. Operating rooms have been
largely shut down, with the limited available access restricted
to patients requiring urgent, life-saving interventions, according
to the recommendations proposed by national societies or
institutional policies. In that setting, deferral of the biopsy
or alternatively fine needle aspiration (FNA) biopsies, can
be proposed. At this moment, we lack information to draw
conclusions on the potentially deleterious consequences this
situation has engendered. It will be of interest to analyze
both the pandemic period and the post-surge period for any
differences in the incidence of new diagnoses of hematological
malignancies, both globally and with respect to indolent and
aggressive types, and to look into whether the deferral of
diagnosis correlates with more advanced stages of disease at
initial presentation.
One of the many consequences of the COVID-19 crisis has
been on clinical trials with restrictions in continuing to enroll
new patients and conduct the clinical trials, including completion
of trial visits and trial assessments. This is due to multiple factors
both on the side of the patients and of the healthcare system:
self-isolation and restrictions of visits to healthcare facilities
required for vulnerable individuals including some trial patients,
clinics allowing only essential or critical visits or refusing to
take part in trials, recruited patients dropping out of trials,
the background of increased pressure on the health service
changing trial staff availability. There may be a need for critical
laboratory tests, imaging or other diagnostic tests to be performed
for trial participant safety or per synopsis of the trial, which
cannot be completed as anticipated. In cases the trial participant
cannot reach the site to have these performed, or the biological
samples cannot be shipped to the central reference laboratory,
the tests may be performed in another local facility. Competent
health authorities (EuropeanMedicine Agency, Swissmedics, and
the Food and Drug Administration) have issued guidelines for
handling the effects of COVID-19 on clinical trials to maintain
the integrity of the trials, to ensure the rights, safety and well-
being of trial participants and the safety of clinical trial staff
during this global public health crisis.
The emergence of the pandemic has highlighted the need
to promote innovative uses of technology to compensate the
reduction or prohibition of in-person meetings and to limit
the exposure risks to health care providers, patients, and
the community. Many cancer centers were forced to cancel
tumor board meetings and went to virtual meetings using
web-based or institutional platforms for communications. In
several pathology departments equipped with slide scanning
instruments, pathologists have been able to review slides remotely
and to provide diagnoses from their homes. While digital
technology is increasingly used for the communication of
histopathological slides, its application to cytological smear
preparations has not yet been widely reported. It will be of
interest to analyze in the near future what we have learned from
the “remote” experience during this period, and which positive
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points can be retained for future practice or in case of future
healthcare crises.
MANAGEMENT OF PATIENTS WITH
ACUTE LEUKEMIA
The treatment of acute leukemia differs significantly between the
United States, in which many novel drugs are FDA approved or
available in clinical trials, and the rest of the world. Moreover,
while in the US intensive induction with daunorubicin and
cytarabine in selected younger patients can administered in
an outpatient fashion, in Europe patients are still hospitalized
until full hematological recovery. Both the American Society of
Hematology (ASH) and the European Hematology Association
(EHA) have released short preliminary guidelines to assist with
the management of some practical issues in AML patients
during COVID-19 pandemic (25, 26). In this chapter, we
will try to briefly summarize the most important components
of diagnosis and treatment, during induction, consolidation,
and maintenance.
Diagnosis
1) All patients with newly diagnosed acute myeloid leukemia
(AML) or acute lymphoblastic leukemia (ALL) should have
a COVID-19 test before admission. As serological tests still
do not have high specificity and sensitivity, the preferred test
is RT-PCR on oropharyngeal/nasal swabs. It is mandatory to
wait for the results before admitting patients in rooms with
positive pressure, in order to avoid the diffusion of the virus
among patients in case of a patient with positive swab.
2) Approximately 50% of the patients with AML/ALL have fever
at diagnosis. Patients with fevers and a blood count and a
peripheral blood smear highly suspicious for acute leukemia
must have a COVID-19 test, and possibly be isolated in a single
room with negative pressure while waiting for the results.
COVID-19 negative patients should move to the hematology
division as soon as the results are available, in order to perform
the diagnostic procedures and start chemotherapy.
3) Bone marrow aspiration and biopsy in all symptomatic
patients with a pending COVID-19 swab test must be
performed wearing personal protective equipment (PPE) with
contact and droplet precautions, including eye protection.
Induction and Consolidation
1) Induction and consolidation therapy in patients with acute
leukemia are associated with a high risk of infectious
complications, due to the prolonged neutropenia that
follows chemotherapy. Accordingly, AML and ALL patients
should have a COVID-19 test before each treatment cycle,
even in the absence of clinical symptoms.
2) In some centers, chemotherapy may have to be delayed or
deferred if the patient tests positive for SARS-CoV-2 or due
to a shortage of isolation beds and/or blood products.
3) A delay of induction chemotherapy by 7–14 days in
AML patients waiting for results of COVID-19 testing
is acceptable during the pandemic, based on recent data
presented by the German group (27).
4) AML patients suitable for intensive induction and with a
negative COVID-19 test should be hospitalized in single
room with reverse isolation and treated with standard
induction. Visitors should not be allowed during the whole
hospitalization, in order to minimize the risk of COVID-19
infection during the hospital stay.
5) Treatment for AML patients not eligible for intensive
therapy should start only if COVID-19 negative. In patients
with rapid progressive disease, hydroxyurea 2–6 g daily can
be used to reduce the tumor burden while waiting for
swab results.
6) The combination of venetoclax and hypomethylating agents
(HMAs) at present is approved by the FDA but not by the
EMA. This treatment, approved for the elderly, is usually
administered in an outpatient setting. Nonetheless, this
combination seems to induce more prolonged bone marrow
aplasia than HMAs alone. Accordingly, it should be used
with caution during the COVID-19 pandemic.
7) The association of arsenic trioxide (ATO) and all-trans
retinoic acid (ATRA) in patients with acute promyelocytic
leukemia (APL) may result in severe respiratory distress
during induction. Accordingly, idarubicin and ATRA are
preferred for induction during COVID-19 pandemic,
followed by ATO + ATRA consolidation, in order to
reduce the relapse rate in patients with low-intermediate
risk profile.
8) Patients with ALL receiving inpatient treatment after testing
negative for COVID-19 can be approached as patients with
AML. While lymphopenia is considered predictive of worst
outcome in COVID-19 patients without hematological
disease, this is yet to be demonstrated in ALL patients.
9) The addition of tyrosine kinase inhibitors (TKI) to standard
chemotherapy in Philadelphia positive ALL does not
result in increased infectious toxicity, and thus should be
continued in COVID-19 negative patients.
10) The use of dasatinib as maintenance therapy post-allogeneic
SCT increases the risk of CMV reactivation and pleural
effusion (28). Accordingly, dasatinib should be used with
caution during the COVID-19 pandemic (9).
11) COVID-19 positive patients with acute leukemia at any
phase of the disease (diagnosis, complete remission,
relapse) should be managed in dedicated COVID-19 unit
if symptomatic, or at home if not symptomatic. Even
if conclusive evidence is still lacking, empiric therapy
with hydroxychloroquine, azitromicin, and enoxaparin
(if platelet count over 30 × 109/l) is current Italian
clinical practice.
12) The equitable utilization of scarce ICU resources for patients
with acute leukemia and severe COVID-19 pneumonia
requiring life support during the pandemic, remains a
very challenging ethical dilemma, which health systems
from different countries have approached in different
ways. Patients who are receiving induction with curative
intent and patients who develop COVID-19 while in
complete remission should be offered ICU care. For patients
with no curative options, relapsed disease, and significant
comorbidities, the decision has to be individualized.
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Relapse
1) Patients with acute leukemia in first or subsequent relapse
should start the treatment only if COVID-19 negative.
2) For patients with relapsed disease, the treatment guidelines of
each center should be followed. If possible, enrollment
in a clinical trial targeting genetic abnormalities is
strongly encouraged.
3) At relapse, molecularly targeted therapy for AML or
blinatumomab/inotuzomab based therapies for ALL patients
should be preferred.
4) Stem cell transplantation after reinduction is still considered
the best treatment option in COVID-19 negative patients
with acute leukemia who did not receive it as a part of their
front-line treatment.
Maintenance
1) The vast majority of protocols for ALL include 2 years
of maintenance therapy after induction/consolidation. As
of March 19th, 2020, GRAALL-14 investigators decided to
skip vincristine and prednisolone during maintenance, whilst
continuing 6-mercaptopurine and methotrexate.
2) Maintenance with HMAs in patients with AML not suitable
for intensive chemotherapy achieving either a complete or
partial response or a stable disease should be continued up
to progression, given the extremely poor outcome for patients
discontinuing HMAs.
MANAGEMENT OF PATIENTS WITH
MULTIPLE MYELOMA
Multiple myeloma (MM) patients are generally old, frequently
frail, and display clinical features, including a poor functional
status, that lead to a high risk of severe COVID-19 infection
and death. MM patients have high rates of co-morbidities,
particularly diabetes, hypertension, chronic obstructive lung
disease, and cardiac diseases, sometimes second malignancies.
They also differ in their urgency of treatment and in
intensity of therapy. Furthermore, the immune system in
patients with MM is compromised at diagnosis by several
factors, which include paucity of functional immunoglobulins
and decreased CD4+ T-cell count. Importantly, low rates
of seroconversion have also been documented in influenza
and pneumococcal vaccination in MM patients. Moreover,
treatments for MM often cause even more immunosuppression:
CD4 counts decrease after proteasome inhibitors (PIs) or
monoclonal antibodies, whereas myelotoxicity, neutropenia,
and decreased T-cell response, frequently follows therapy with
immunomodulatory drugs (IMiDs).
Steroids, a backbone agent in most MM regimens, are well-
known to exert immunosuppressive activity, particularly when
combined with IMiDs and PIs. Lymphopenia may worsen
after starting therapy with some monoclonal antibodies (i.e.,
elotuzumab). The slow and sometimes incomplete hematopoietic
recovery and the prolonged immunosuppression observed in
patients who receive autologous stem cell transplantation
(ASCT) is another factor. All these findings make MM patients
probably more susceptible to COVID-19 infection and support
the assumption that they are at increased risk for poor
outcomes if infected by SARS-CoV-2. While data confirming
these assumptions are needed, it is important to decrease at the
upmost the risk of SARS-CoV-2 exposure in MM patients.
There are still not sufficient data to produce evidence-based
recommendations, so that only consensus statements have been
so far published in this setting (22–24, 29–31). Therefore, we will
provide here our personal suggestions, based on experience, on
the management of MM patients during the ongoing COVID-
19 outbreak.
General Measures to Prevent COVID-19
Infection in MM Patients
Hospital admission and recurrent hospital visits increase the
risk of COVID-19 infection, as asymptomatic individuals can
transmit the virus. Therefore, efforts should be made to minimize
patient exposure to COVID-19, by decreasing physical contact
with the health care system, avoiding non-essential visits and
minimizing the time spent by patients in infusion suites and
other clinical areas. However, to avoid compromising patient’s
outcome by excessively postponing diagnosis or treatments,
hematology departments should ensure full operative activity.
Hematologists should actively elaborate protocols to control the
spread of the infection through an adequate patient flow. All
healthcare professionals should follow these procedures aiming
to maintain “COVID-19 free” sectors, and reduce infection risk
of other patients within the community of subjects followed at
the same center.
As a general rule, we recommend COVID-19 testing (PCR)
for all patients with newly diagnosed MM before starting any
cycle of chemo or immune-therapy, before stem cell mobilization
procedures and before ASCT. Treatment for MM, in fact, can
worsen the symptoms of an active COVID-19 infection in these
patients. Validated serological tests, could at some point also
be useful for identifying patients who developed and recovered
from COVID-19. Screening should be done for both outpatient
and hospitalized patients, before initiating therapy. Healthcare
professionals should also be quarantined and undergo COVID-
19 testing (PCR) if a contact with a positive patient does occur. A
positive PCR or a positive IgM or IgA test should be considered
as “active COVID-19.”
Patient education is paramount. Social distancing, staying
home (except for treatment), washing hands frequently with
soap (for at least 20 s), covering coughs and sneezes with masks,
and cleaning frequently touched surfaces represent pivotal
and effective component of mitigating the risk of COVID-19
infection and are all strongly recommended.
Patients, staff and relatives should be triaged for symptoms
and exposure to COVID-19 before entering the health care
facility. Families, in particular, should be informed of the
importance of reporting early respiratory symptoms, fever,
or contact(s) with symptomatic people before having any
interaction with the MM patient or close relatives. Medical
visits, routine laboratory testing, catheter maintenance, and
invasive procedures should be scheduled only if really necessary,
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and only for asymptomatic patients, in a COVID-free area.
Implementation of telemedicine via audio or video technologies
should be pursued to reduce patient exposure to SARS-CoV-2.
Alternative and innovative methods of communication, such as
bloodwork-monitoring at home/local laboratories or couriering
of medications to patients’ home may also be required to
further minimize risks. Social support including tips for coping
with stress should be also provided to the patient and their
family members.
Regarding personal protective equipment (PPE), appropriate
droplet-contact protections throughout the entire patient clinical
assistance should be used, as SARS-CoV-2 can be transmitted,
by asymptomatic carriers, before the beginning of clinical
symptoms. Single use gloves are also recommended.
Approach to Smoldering Multiple Myeloma
All patients with smoldering MM, according to current
guidelines (32), should be monitored with no active intervention.
In absence of symptoms or clear signs of laboratory/imaging
evolution, tele-consultation should be the approach of choice.
If possible, consider delaying with close follow-up if there is no
imminent risk to the patients, such as diagnosis by SLiM criteria
without any other end organ damage.
Newly Diagnosed Patients Eligible for
ASCT
High dose melphalan followed by ASCT is the treatment of
choice for younger patients with newly diagnosed MM who
are eligible for such a procedure (33). However, balancing
the risks of COVID-19 infection and MM-related mortality is
difficult and, therefore, in the current setting of the COVID-19
pandemic, deciding whether ASCT has to be performed, delayed,
or excluded should be carefully evaluated on a case by case basis.
Although the necessity for intensive care after ASCT occurs
only occasionally, it should be considered the risk of a possible
shortage of ventilators and intensive care beds, putting MM
patients who receive ASCT at increased risk, once they should
require these interventions. COVID-19 outbreak could also
negatively affect the availability of blood and platelet products,
as the number of blood donors might decrease with the
recommendation to self-isolate. Prolonged post-ASCT aplasia
and, above all, the long time required for a complete immune
reconstitution, should also be taken into account. Upfront ASCT
for older adults (>70 years) with MM should be, at present
time, omitted.
Several studies have evaluated upfront vs. delayed ASCT and,
overall, they support the potential lack of a negative impact,
at least on survival, of delaying ASCT (34–36). Thus, ASCT
could be safely postponed for a pre-determined period of time
for standard risk patients at least in very good partial response
after induction therapy. In these cases, the prolongation of the
treatment for up to six cycles may be a recommendable option.
In standard-risk patients achieving a CR with or without negative
minimal residual disease, initial therapy could be extended for
up to nine cycles, delaying ASCT until the epidemic subsides
or, alternatively, starting maintenance and preserving ASCT for
the first relapse, as salvage therapy. In this scenario, however, it
would be necessary to avoid treatments with stem cell poisons,
in order to retain the ability to harvest hematopoietic stem
cells afterwards. In patients with confirmed, recent COVID-19
infection, it is wise to delay stem cell collection; nonetheless,
in some red zones, delaying stem cell collection should not
be an option, but a necessity. Indeed, stem cells collection
during front-line treatment may be not required for every
patient. Conversely, patients with rapidly progressive disease,
high cytogenetic risk (especially deletion of chromosome 17p), or
those with plasma cell leukemia or extramedullary disease, should
not postpone ASCT.
Newly Diagnosed Patients Not Eligible for
ASCT
Most elderly patients with MM are treated as outpatients, with
frequent visits to the hospital (23). Risk stratification remains
important, as well as the decision of whether the need for
treatment is urgent or not. To optimize care of older patients with
MM during this pandemic, decisions regarding dose-reductions,
regimen modification/interruptions or continuation of therapy
will need to be to be made, again, on a case by case basis. In
this setting, while myeloma staging criteria (37) and geriatric
assessment tools (38) have not been shown so far to assist with
predicting for COVID-19 outcomes, they can be utilized for
adapting the treatment of older adults with MM during this
challenging time.
Patients with aggressive disease, defined by the presence
of anemia, renal dysfunction, hypercalcemia, leukemic, or
extramedullary presentation, or high-risk cytogenetics, need to
start treatment as soon as they can, as they have a higher risk of
dying for myeloma than COVID-19.
Induction treatment with regimens including only oral
drugs should be pursued in frail patients (elderly and/or with
comorbidities). These regimes require fewer visits (generally
every 4 weeks), thus reducing the risk of SARS-CoV-2 exposure.
Fit patients can be treated with standard therapies. We do not
suggest any specific regimen, because available data regarding
specifically COVID-19 and myeloma therapy are lacking. The
choice of the treatment, which includes combinations containing
bortezomib and/or lenalidomide, should be performed on
the basis of previously established criteria, particularly the
presence of renal failure, cytogenetics, thrombotic complications,
extramedullary disease, or peripheral neuropathy. If any adverse
event occurs, it should be considered dose reduction or dose
delay, prolonging the interval between cycles. In particular,
bortezomib should be administered weekly and using a
subcutaneous route, and then every other week after 6–8 cycles,
if a good and sustained response is obtained. Given the possible
detrimental effect of steroids on patient outcome reported form
previous coronavirus outbreaks, it should be considered to
reduce the weekly dose of dexamethasone from 40 to 20mg, to
decrease the risk of infectious complications. In selected cases,
in complete remission, dexamethasone should be omitted, while
receiving continuous treatments. Finally, dexamethasone should
be administered orally, in an outpatient setting.
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Aiming to reduce potential exposure to COVID-19, we also
recommend to decrease the frequency of blood work at the
essential. In patient with adequate bone marrow reserve, blood
work can be checked before starting the next cycle, rather
than every week. Telemedicine should be the preferred way to
monitor patients receiving treatments or in follow-up. Finally,
pharmacists should be able to provide prescription doses for 2–
3 months of treatment at a time, instead of the usual 1 month.
Finally, home care, whenever possible, and switching from an
intravenous or subcutaneous treatment to a fully oral treatment
combination should be considered.
Relapsed Patients
Most patients with MM relapse, but since not all relapses are
the same, the main issue to consider is the time to initiate
subsequent-line treatments. For clinical and more aggressive
relapses, resulting in worsening end organ damage, subsequent
treatment cannot be postponed. By contrast, active treatment for
standard-risk patients, experiencing biochemical relapse, should
be delayed. We do not recommend any specific regimen for
relapsed patients, since no specific data is available on MM drugs
and COVID-19, and thus only suggestions can be provided.
Regarding daratumumab-based regimens, an infusion time of
90min, after the third dose, in the absence of prior infusion
reactions, may be used. Furthermore, after the achievement of
at least a very good partial response, the subsequent schedule
could be changed to a dose every 4 weeks instead of every
2 weeks. When the goals of therapy are achieved, and after
10–12 cycles, we suggest to consider switching to maintenance
with lenalidomide. Carfilzomib should be administered once-
weekly instead of twice-weekly in order to reduce the number
of patients’ admissions to health care units, depending on the
combination regimen and dosing. Finally, fully oral treatment
schedules should be preferred over intravenous or subcutaneous
treatments, and switching from one kind of treatment (i.v. or s.c.)
to another (oral) should be considered, on single case basis.
In relapsed patients supposed to receive ASCT as a part
of the treatment plan, it should be carefully evaluated, on
single case basis, to eventually delay transplant until the current
pandemic resolves. For example, we recommend to proceed with
ASCT without any delay in patients with aggressive relapse and
suboptimal responses to salvage therapy). On the contrary, ASCT
should be delayed in patients relapsing slowly and achieving deep
responses with salvage therapy.
Maintenance
Maintenance with oral drugs should be continued, without
dosing modification and or interruption, in the absence major
adverse events. If steroids are part of the regimen, a progressive
tapering of the dose, until interruption, should be considered.
Again, teleconsulting should be preferred for monitoring patients
during COVID-19 pandemic. Blood testing should be performed
by patients in the closest laboratory, and visits could be
performed over the phone. Hospital visits should be performed
every 3 months.
Supportive Care
Anti-thrombotic prophylaxis (with a particular attention to
the temporary use of heparin), as well as prophylaxis against
varicella-zoster virus with acyclovir and against pneumocystis
jirovecii with sulfa, remains unchanged as before the COVID-
19 pandemic. Any additional anti-microbial prophylaxis is not
recommended at the present time. Testing for other etiologies,
such as influenza and other respiratory pathogens, may be
required if symptoms appear. Vaccination, especially against
influenza and pneumococcal species, is very important, as well
as vaccination of family and contacts. Bisphosphonates such as
zoledronic acid may be held for patients with stable disease and
in the absence of significant bone related-disease. For other cases,
we recommend using zoledronate every 3 months, rather than
monthly, and the interruption in patients in complete response
who received at least 2 years of treatment. Switching from an
intravenous to an oral bisphosphonate may be a valid option.
Patients should be also advised to take calcium and vitamin D.
The use of growth factors should be evaluated on single case basis,
and long-acting growth factors should be considered.
Clinical Trials
Involving patients in a clinical trial remains an appropriate
strategy to consider for all MM patients, as it allows access
to off-label, highly beneficial drugs or combinations that
can be otherwise unavailable, especially for patients with
advanced disease. Therefore, this participation, once patients
have been enrolled, should, in principle, continue. Nonetheless,
we recommend every single institution to carefully weigh the
advantages and disadvantages of including any single patient in
a clinical trial, also considering the spread of SARS-CoV-2 in
specific areas of the world.
Nevertheless, patient safety remains the priority. As a
consequence, many centers have modified their protocols,
allowing, for example, blood draws to be done locally,
telemedicine evaluation whenever possible, and home or
extended delivery by hospital pharmacies of the medication(s)
under investigation, in order to reduce or avoid hospital visits.
In general, we do not suggest, despite the current COVID-
19 pandemic, to suspend or slow enrollments, if appropriate
measures are applied.
Regarding COVID-19 infected MM patients, such a condition
should be an opportunity for collecting precious clinical data;
performing prospective studies for the management of the
infection and its severe complications, should be also stimulated.
COVID-19 Positive Patients
For COVID-19 positive patients we recommend holding
treatment for at least 2 to 3 weeks, depending on the clinical
need. Antineoplastic therapy should be reintroduced only after
complete convalescence, ensuring safety. Metabolic and bone-
related acute complications can be instead managed with
adequate supportive care. It is not knownwhether an IgG positive
serology test indicates that myeloma treatment can be initiated
as usual.
Currently there are scarce published data regarding both
the prevalence and outcomes for patients with MM exposed
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to COVID-19. In general, we can expect that the COVID-19
infection pattern ofMMpatients will be similar to that of patients
with solid cancers, but no data support this estimation so far.
Some data from the International Myeloma Foundation have
shown that, until April 30, 2020, few MM patients have tested
positive for COVID-19 and are almost all doing well in the Asia-
Pacific region, as well in US, with rare exceptions. More COVID-
19 cases were observed up to now in Italy, Spain, and France, and
some of them died from the infection. Deaths have been reported
mostly in fragile elderly patients and in end-stage disease.
A UK survey of 75 COVID-19 positive symptomatic patients
with MM receiving active anti-myeloma therapies, whether
managed in the inpatients or outpatient setting, has been recently
reported (39). At the time of publication, 41 patients (54.6%),
had died. Nine patients required critical care support and all
deceased. Mortality was associated with multiple comorbidities,
older age, and Afro-Caribbean origin. A very few patients
received ruxolitinib, tocilizumab, or hydroxychloroquine.
From February 25 to May 18, 2020, 94 hospitalized patients
with MM were included in a large, nationwide study of COVID-
19 positive patients with hematological malignancies in Italy
(NCT04352556). Some of them had admission to intensive care
units requiring assisted ventilation or died during the pandemic.
Various treatments with antiviral agents, hydroxy-chloroquine,
heparin, or tocilizumab were also employed. Detailed data on this
study will be soon available.
Clinical experience is accumulating with patients with MM
infected by COVID-19. Close monitoring is crucial in SARS-
CoV-2 patients in self-isolation at home, with asymptomatic
or paucisymptomatic infections, as clinical deterioration may
happen at the end of the first week. It is well-known that the risk
of thrombosis is already increased in MM patients, especially in
the early phase of treatment, at relapse, or in patients receiving
thalidomide or lenalidomide treatments. Furthermore, there is
increasing evidence that COVID-19 infection per se increases the
risk of thrombosis and endothelitis. Clinicians should evaluate
the risk of thrombosis on single case basis, and evaluate the
prophylactic or therapeutic use of anti-thrombotic drugs. Given
some positive results with heparin in subjects positive for
COVID-19, such a treatment could be a recommended option
in these patients.
Until now, no specific clinical trials of COVID-19 directed
therapy in MM have been published. Some patients treated
with tocilizumab, a monoclonal antibody directed against IL-6
receptor, had a positive outcome (40, 41). In a case we recently
observed, however, such a treatment was not effective.
Conclusions
The COVID-19 era is challenging and the management of MM
patients should be based on strict collaboration between patients,
clinical staff, health care institutions and families. A summary of
the currently available recommendations and a detailed decision-
making algorithm for the management of patients with MM
during COVID-19 pandemic has been very recently reported
by the European Myeloma Network (EMN) (31). Although
shared guidelines should be adopted, when possible, many cases
will be evaluated on an individual basis, focusing on disease
characteristics as well as on patient’s history. Any effort should be
done tomanageMMpatients in any phase of the disease to ensure
that they will receive the most efficacious treatment, and their
prognosis will not be negatively affected by the current pandemic.
Ongoing data collection efforts will be fundamental to filling the
existing knowledge gaps about the epidemiology, treatment, and
outcomes of COVID-19 for MM patients in the near future (42).
MANAGEMENT OF PATIENTS WITH
LYMPHOMA AND CLL
The issues relevant to the management of patients with
lymphoma and CLL during the COVID-19 pandemic can be
broken down as follows:
1) Diagnosis, staging, risk assessment, and initial
laboratory evaluation
2) Treatment decisions in patients who are COVID-negative
a) High grade lymphomas with front line curable options
b) Aggressive curable non-hodgkin’s lymphomas and
Hodgkin’s lymphoma
c) Indolent lymphomas and CLL
3) Treatment decisions in patients who are COVID-positive
4) Supportive care and monitoring of toxicity
Diagnosis, Staging, Risk Assessment, and
Initial Laboratory Evaluation
The diagnosis and initial assessment of patients with suspected
or newly diagnosed lymphoma and CLL has to be adapted
to the existing isolation and travel restriction rules. In-person
visits should be minimized and most visits should be performed
via Telehealth, including new patient visits and consultations.
Imaging and staging procedures should be consolidated. Biopsy
techniques that do not require anesthesia and surgical procedures
are preferred, and CT or ultrasound guided core needle
biopsies are recommended. FNAs should be avoided. Long
term venous access modalities that requires less frequent care
should be utilized. The use of chemotherapy-clearance tests
in low risk patients who need immediate access to therapy
(PFTs/Echocardiogram in young healthy patients) may need
to be reconsidered. Infusion centers overcrowding should be
avoided. Oral chemotherapy options and home therapy should
be pursued.
Treatment Decisions in Patients Who Are
COVID-Negative
Aggressive Non-Hodgkin’s and Hodgkin’s Lymphoma
The cure rate for diffuse large B-cell lymphoma (DLBCL) is
∼60–70%, with rituximab-based chemoimmunotherapy, such as
R-CHOP or similar combinations (43). These are outpatient
regimens given every 3 weeks, do not require interim visits in
the absence of complications, and therefore are a good treatment
option during the COVID-19 pandemic. Intensive transfusion
support is not required in most patients with DLBCL, except in
the elderly (44). For patients with double hit lymphomas (DHL)
R-CHOP is inadequate and DA-EPOCH-R has emerged as the
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standard of care in the US. Given the appropriate resources, DA-
EPOCH-R can be given as an outpatient in selected patients
in the U.S, starting with cycle 2, after inpatient completion of
cycle 1 without complications. The same approach is used for
patients with primary mediastinal B-cell lymphomas (PMBCL),
especially in cases where a radiation-free strategy is desired.
At the Sidney Kimmel Cancer Center, since 2018, we have
established an active outpatient DA-EPOCHprogram for DLBCL
patients, thanks to a well-organized and robust outpatient home
infusion service (Jefferson Home Infusion Service - JHIS).
In cases where outpatient DA-EPOCH-R is not doable, R-
CHOP-21, with involved field radiation for PMBCL, is an
acceptable alternative during the pandemic. Given the availability
of subcutaneous formulation, the administration of rituximab is
also logistically easier. Despite theoretical concerns that filgrastim
may exacerbate the respiratory effects of COVID-19 infection, in
cases where severe myelosuppression is expected, growth factor
support should be used, with the best option of Peg-filgrastim
with on body injector (Onpro R©).
The management of patients with aggressive lymphoma and
high-risk for CNS relapse was a challenge before COVID-19 and
the dilemma has now been further exacerbated by the logistical
constraints imposed by the pandemic. While intrathecal (IT)
chemotherapy with methotrexate, given on the same day of
R-CHOP for the first 3–4 cycles, is feasible in the outpatient
setting, its efficacy in high risk patient is low, especially in
preventing parenchymal involvement, and the recent trend has
shifted to providing prophylaxis with high-dose methotrexate
(HDMTX), often given on day 15 of each R-CHOP cycle, for 2–
4 doses, depending on patients’ characteristics and presentation.
Since integrating HDMTX with DA-EPOCH-R is extremely
challenging, in light of the excessive myelosuppression and non-
hematologic toxicity, CNS prophylaxis in patients with DHL who
are at very high risk, often has to fall back on IT methotrexate.
Alternatively, two doses of HDMTX given after completion of six
cycles of DA-EPOCH-R is an option.
Considering that the orchestration of combined modality
therapy is logistically more complex than single modality
therapy, patients with non-bulky (<10 cm) limited stage DLBCL
can be treated with R-CHOP X 4, without the need for radiation
or radio-immunotherapy, based on recent data from the FLYER
trial (45). In the presence of bulky disease, or when radiation
therapy is indicated according to best clinical judgement, hypo-
fractionated RT regimens are recommended, according to recent
guidelines (46).
For patients with relapsed/refractory DLBCL that is
chemosensitive to second-line chemotherapy high-dose
chemotherapy (HDC) with ASCT, with minimal or no delays,
remains the optimal therapy in light of its curative potential
(see section on Cellular Therapy below). There is no preferred
second line regimen for DLBCL. Options include oral therapy
with lenalidomide-based regimens, chemoimmunotherapy
with bendamustine and rituximab, which has the advantage
of being administered every 28 days, and R-Gem-Ox which
can be administered in split doses every 14 days. Polatuzamab
and Bendamustine, approved in the third-line setting in the
US) is another option. In light of the logistical complexity and
the probability of utilizing scarce ICU beds CART-cell therapy
remains minimally used during the pandemic.
Hodgkin’s disease is a highly curable malignancy and every
effort should be made to avoid treatment delays and maintain
dose intensity and keep therapy on schedule. For patients with
early stage favorable classic Hodgkin lymphoma (cHL) two
cycles of ABVD and limited radiotherapy (20Gy) remains the
standard of care, but–as for limited stage DLBCL–the logistical
burden of administering combined modality therapy during the
pandemic is high. An alternative is the use of PET-adapted
single modality therapy with four cycles of ABVD (47). At
the SKCC we are omitting bleomycin from ABVD in early
stage patients with a negative interim PET2, extending the
data from the RATHL (response-adapted therapy for advanced
Hodgkin lymphoma) clinical trial to patients with early stage
favorable cHL (48).
For patients with early stage, unfavorable cHL (bulky
mediastinal mass, B symptoms, elevated ESR, multiple nodal
sites) acceptable standards of care include PET-adapted single
modality therapy with ABVD x 4–6 (especially for those
who are unfavorable for reasons other than bulky disease) or
combined modality therapy with ABVD X 4 + involved site
radiotherapy (ISRT). Once again, single modality is preferred, if
possible. Omission of bleomycin after a negative PET/CT is also
appropriate for these patients.
For patients with advanced stage cHL the recommended
approach remains single modality PET-adapted ABVD, with
the intent of eliminating bleomycin after cycle 2 in PET2-
negative (Deauville 1–3) patients. For patients with a positive
(Deauville 4–5) interim PET/CT most centers in the U.S.
do not transition immediately to dose-escalated BEACOPP
but rather proceed with additional ABVD therapy and repeat
a PET/CT. An alternative to this regimen in the US, is
AVD with Brentuximab vedotin, according to the recently
published ECHELON-1 trial. This regimen has not yet been
universally embraced in the US, in part because of the
increased myelosuppression, requiring for routine growth
factor support, and the high rate of sensory peripheral
neuropathy (SPN).
Older patients (variably defined, most often >60 years) with
cHL are a high-risk category, with inferior outcomes. AVBD
remains the standard of care, with omission of bleomycin inmost
or all cycles, but with an increased risk of myelosuppression and a
high rate of hospitalization. For patients who are frail and elderly,
not ASCT eligible, and experience significant toxicity with the
first cycle of AVD, single agent brentuximab vedotin (BV) can
be explored on a compassionate basis.
During the pandemic, even for fit, young, intent-to-transplant
patients with relapsed or refractory cHL, second line regimens
that do not require hospitalization such as gemcitabine- and
bendamustine-based regimens are preferred. BV or immune
checkpoint inhibitors (every 4 weeks) can be used. Our approach
at the SKCC is to proceed to ASCT in all patients with R/R cHL
who have chemosensitive disease, and our BMT program has
remained open. In selected patients with R/R cHL, especially for
older patients and patients with late relapses, or at centers where
BMT programs have stopped their operations, it is acceptable
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to consolidate responses to second- or third-line therapy with
radiotherapy instead of ASCT.
Indolent Lymphomas and CLL
The primary focus for indolent B-cell and T-cell lymphomas
(such as CTCL) in the setting of COVID-19 should be safety
for the patient and reduction of the risk of exposure for
patients and HCT. Consensus guidelines for CLL and indolent
lymphomas have long routinely supported watchful waiting and
initiation of therapy only when there is a clear indication.
These criteria remain valid and should be followed even more
strictly during the pandemic. Decisions should be made on a
case by case basis and according to best clinical judgement,
but if the indication for therapy is questionable, treatment
deferral with repeat imaging and close monitoring should be
offered to the patient. While the risk benefit calculation of
administering single agent rituximab in asymptomatic patients
with follicular lymphoma (FL), marginal zone lymphoma (MZL),
and other low-grade B-cell lymphomas has often fallen on the
side of initiating therapy, especially in patients uncomfortable
with treatment deferral, these considerations need to be
revised during the pandemic. In light of the possible adverse
impact of hypogammaglobulinemia on COVID-19, treatment of
asymptomatic patients with rituximab is not recommended and
should be discouraged.
When treatment is indicated (49), the risks and benefits
of rituximab monotherapy vs. chemo-immunotherapy should
be carefully considered. Patients with localized, symptomatic
disease should receive single modality radiotherapy. While
radioimmunotherapy remains an underutilized treatment option
for relapsed and refractory FL, it has the advantage of
requiring only a short course of therapy, with high efficacy and
should be considered in selected patients. The only available
radioimmunotherapy agent at this time is ibritumomab tiuxetan
(Zevalin). Patients with indolent B-cell lymphomas and high-
risk features according to GELF may have greater clinical
benefit from chemo-immunotherapy, such as R-CVP or R-CHOP
with growth factor support, rather than single agent rituximab.
Maintenance rituximab, with its clinical benefit limited to
progression free survival (PFS), is discouraged during the
pandemic. If maintenance rituximab is used, immunoglobulin
levels should be carefully monitored, especially in older patients.
Patients with comorbidities, recent infections, and documented
hypogammaglobulinemia, whether or not it is secondary to
rituximab, may benefit from monthly IVIG. In COVID-positive
patients, especially patients with CLL and recurrent infections,
IVIG can be continued, although given the higher risk of
thromboembolism during COVID-19, this decision should be
made on a case-by-case basis and patients should be monitored
for symptoms of thromboembolic disease.
Since initial approvals in 2013, 2014, and 2015 for patients
with relapsed Mantle Cell Lymphoma (MCL), CLL/SLL, and
Waldenstrom, respectively, ibrutinib has become an essential
component of the therapeutic toolbox for these B-cell neoplasms
and remains a good treatment option in the US. Ibrutinib appears
to be safe during the pandemic and no new signal of toxicity
has been reported. In fact, anecdotal cases have suggested that
ibrutinib may have a protective effect on COVID-19 pulmonary
injury in patients with Waldenstrom (50). Data on more recent
BTK inhibitors are not available. One advantage of ibrutinib and
other oral agents, such as lenalidomide is that they limit the
number of visits to the outpatient clinic, therefore reducing the
patient’s risk of contracting COVID-19. We have utilized this
approach, with labs obtained locally and telehealth visits for most
of our patients with indolent lymphomas.
Symptomatic patients with CLL represent a high-risk
population during the COVID-19 pandemic because of their
underlying immunodeficiency and documented inadequate
immune response to infections. These patients are at high risk
of bacterial infections and reactivation of latent herpesvirus
infections, such as HSV, VZV, CMV, and EBV. Whether or not
patients with CLL have a disproportionately higher incidence of
severe COVID-19 compared to patients with other malignancies
is not known.
As in other indolent B-cell neoplasms, initiation of treatment
in CLL patients should be deferred if possible and the iwCLL
guidelines should be used to assist with treatment decisions
(51) For symptomatic patients who require immediate therapy,
treatment decisions should bemade based on disease and patient-
specific factors, with preference for oral agents and therapies
that can be given in the outpatient setting. The goal is to
expose the patient to fewer clinic visits and lab assessments.
Considering that recent studies in patients with untreated CLL
(52, 53) have demonstrated that the addition of rituximab to
ibrutinib has thus far not provided added benefit in terms of
response rates or survival, avoiding treatment with rituximab,
and obinutuzumab in these patients during the pandemic is a
very reasonable approach.
The use of another highly effective drug in CLL, venetoclax,
has been generally discouraged during the pandemic because
it typically requires multiple and extended clinic visits, with
dosing ramp up and lab testing, to monitor for tumor lysis
syndrome (TLS). However, patients with ibrutinib-resistant CLL
and patients with high risk CLL, such as those with 17p deletion,
may not have other good treatment options.We have successfully
administered venetoclax to elderly patients with refractory CLL
in the outpatient setting with remote Telehealth monitoring and
frequent blood draws and laboratory monitoring for TLS using
Jefferson Home Infusion Services.
While the experience remains anecdotal, it appears that
COVID-positive CLL patients who are asymptomatic or have
very mild symptoms, can safely continue therapy. However,
treatment decisions for patients with more symptomatic
COVID-19 have to be based on assessing whether the patient
will incur more risk from the CLL or from the theoretical
possibility of developing severe COVID complications,
due to therapy. Although there is a degree of consensus
that anti-CD20 monoclonal antibodies should be held in
COVID-positive CLL patients, because of the concern for
severe hypogammaglobulinemia, treatment decisions, such
as holding or continuing therapy, should be made on a
case-by-case basis. For patients receiving BTK inhibitors,
discontinuation can result in CLL flares and cytokine release
that mimic COVID-19, so judgment should be exercised
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and COVID-19 testing may need to be included in the
treatment algorithm.
MANAGEMENT OF PATIENTS RECEIVING
STEM CELL TRANSPLANTS AND
CELLULAR THERAPY
The COVID-19 pandemic posed unique challenges to
hematopoietic cell therapy (HCT) and immune effector cell
therapy (IECT) programs, not only in the United States but on
an unprecedented global level. The inherent medical complexity
of these procedures, coupled with the intricate network of
logistical, operational, and regulatory steps they require, had to
be approached with agile and frugal planning. Agility, because
of all the obfuscations surrounding the pandemic timeline, the
initial lack of availability of COVID-19 testing, and later on
antibody testing, and an interminable list of uncertainties and
moving sand. Frugality because of the strain that the pandemic
caused on resources, staff, and on the stem cells and effector
T cells supply chain. COVID-19 specific guidelines for HCT
from the American Society of Transplantation and Cellular
Therapy (ASTCT) and the European Bone Marrow Transplant
(EBMT) are rapidly evolving. However, these recommendations
do not account for transplant centers’ variability in terms of
available resources or surge patterns. Laid bare, this pandemic
took everyone by surprise! On March 13, 2 days after the WHO
declared the COVID-19 a pandemic, we devised a congruent
model to deal with the new reality. For this brief introduction,
we will summarize The Sidney Kimmel Cancer Center (SKCC)
program’s experience (for context), with a focus on three
particular aspects:
1) Managing the workflow
2) Deferring IECT and non-urgent high dose chemotherapy
(HDC) procedures
3) Securing safe allogeneic stem cell grafts
The Workflow of the Clinical Care Team
We designed a two-team model, one for managing the
inpatient unit and the second to carry out the outpatient
operation. Continuity of care was maintained through virtual
communication between the two teams. Additionally, members
of the same team limited their in-person interactions to the
absolute minimum. Approximately 75% of in-person clinic visits
were effectively converted to our institution’s telehealth platform,
a silver lining of this pandemic that will likely stay with us.
We limited the exposure of hospitalized patients to a minimal
number of the inpatient care team, in the vast majority of
cases, the daily physical interaction was limited to one nurse
and one physician excluding consulting services when needed.
Daily roundtable morning rounds were leaned out to the bare
minimum of clinical staff with virtual participation from ancillary
services. All incoming new or re-admitted patients were properly
screened for COVID-19 before entering the inpatient unit, and
a strict no visitors policy was implemented. Finally, we retained
the nursing staff to work exclusively in the inpatient unit and
eliminated the need for nurse floaters from other services. This
comprehensive model effectively limited the risk of COVID-19
nosocomial exposure and ensured adequate backup coverage for
team members who may get infected or need to be quarantined
for inadvertent exposure. As of the timing of writing this
manuscript, on June 1, 2020, our inpatient unit remains COVID-
19 negative, and none of our clinical staff members or patients
experienced nosocomial exposure.
IECT Procedures and HDC Procedures
Our IECT portfolio includes industry-sponsored actively
accruing chimeric antigen receptor T-cell (CAR T) trials for
CLL, MM, metastatic castration-resistant prostate cancer, and a
variety of solid tumors. We are also an approved center for the
two commercial CAR T products. Since mid-March 2020, all
industry-sponsored research and commercial CAR T procedures
were suspended at our institution. Patients who were eligible
for this treatment were treated with alternative therapeutic
modalities or kept under close monitoring. Screening for CAR
T research protocols continued in order to identify patients who
should be prioritized in the post-surge phase.
All eligible lymphoma patients proceed to HDC with no
deferment. All eligible multiple myeloma and amyloid disease
patients for HDC were deferred for a brief period. However,
on April 21, 2020, we decided to proceed with treating all the
deferred cases. Many factors contributed to the reversal of the
deferment and resumption of HDC procedures. Our institution’s
projection for COVID-19 infection in the Philadelphia area
indicated a flatter more prolonged surge curve compared to a
steeper curve in neighboring New York City. The improved
and wide availability of the rapid COVID-19 testing allowed for
more efficient screening of all patients on the admission day.
Finally, our piloted workflow management strategy has proven
to be safe and effective in creating enough capacity to handle
all deferments.
Securing Safe Allogeneic Stem Cell Grafts
No routine COVID-19 testing was provided for asymptomatic
HCT donors. Once patients were started on their conditioning
regimen, donors were instructed to self-quarantine and report
any suspicious symptoms. All matched and unmatched related
donor HCT procedures proceeded without deferment per
our program post-transplant cyclophosphamide (PTCy) T cell
tolerization two-step protocols (54).
Consistent with the recommendations of the national marrow
donor program (NMDP), cryopreservation was required for
all unrelated donor stem cell grafts. In line with the recent
Center for International Blood and Marrow Transplant Research
(CIBMTR) data (55) we successfully utilized post-transplant
high dose cyclophosphamide after cryopreserved stem cell
products with proper, timely engraftment and no increased short-
term complications.
CONCLUSIONS
The COVID-19 pandemic presents a challenge that is
unparalleled in recent times and has created unprecedented
medical, logistical, financial, and public health hurdles to the
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delivery of optimal care for patients with cancer, and in particular
those with hematologic malignancies. While robust data are
still missing, preliminary observations, and experience with
other endemic or seasonal viral respiratory infections suggest
that the greater degree of immunocompromise, due to either
the primary malignancy or the severe myelosuppression and
lymphodepletion associated with intensive chemotherapy
regimens, is likely to expose patients with hematologic
malignancies to a greater risk of SARS-CoV-2 infection and
severe clinical outcomes during COVID-19. Curative therapy
for many patients with hematologic malignancies requires the
use of dose intensive chemo-radiation protocols, followed by
autologous or allogeneic SCT. Health care systems have rapidly
adapted to these challenges and access to life saving and life
prolonging therapies has remained available. The technology
explosion of Telehealth and home care platforms has allowed
patients to remain in contact with their HCT and has allowed
management and follow up of patients requiring therapy during
the pandemic. While routine elective procedures were deferred
for a while, scheduling and performance of the diagnostic,
staging, and chemotherapy clearance procedures has resumed,
but much was learned in terms of same day consolidation all
the diagnostic and staging procedures. In some cases, what was
once thought to be impossible has become a normal routine.
COVID-testing platforms have been expanded remarkably,
and serological testing is becoming more available. Clinical
trial operations have remained open, if scaled down, in many
institutions during the pandemic, and study logistics, including
consenting, sample acquisition and transportation, and study
visits have been made more flexible. While the peak of the
pandemic may soon be past, in the absence of a vaccine, the
risk of additional waves of infection remain, and our level or
alertness and the operational response to future challenges need
to be maintained.
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